6533b858fe1ef96bd12b5b51
RESEARCH PRODUCT
Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications
A VitaleF FarinatiM FinottiC Di RenzoG BrancaccioF PiscagliaG CabibboE CaturelliG MissaleF MarraR SaccoEg GianniniF TrevisaniU CilloS BhooriM BorzioP BurraA Casadei GardiniP CarraiF ContiR CozzolongoA CucchettiR D'ambrosioC Dell'untoN De MatthaeisGg Di CostanzoS Di SandroS FamularoFg FoschiF FucilliG GalatiM GambatoA GasbarriniF GiulianteD GhinolfiA GriecoS GruttadauriaM GuarinoM IavaroneA KostandiniQ LaiI LenciGv Levi SandriF LositoLg LupoG MarascoTm ManziaS MazzocatoM MasaroneF MelandroC MescoliL MieleF MoriscoM MuleyD NicoliniD PaganoM PersicoM PompiliFr PonzianiR PravisaniGl RapacciniM RendinaM RenzulliF RomanoM RossiE RrekaFp RussoA SangiovanniA SessaN SimonettiC SpositoR TortoraL ViganoM ViganoE VillaV VincenziP VioliF AzzaroliMr BrunettoA Di MarcoA GasbarriniFg FoschiM GuarinoA MasottoA MegaF MoriscoG NardoneF OliveriG RaimondoGl RapacciniG Svegliati BaroniG VidiliM Zolisubject
Cancer Researchmedicine.medical_specialtyReviewlcsh:RC254-282Prognostic score03 medical and health sciences0302 clinical medicinemedicineIn patientMedical physicsStaging systemmonotonicity of gradientsSettore MED/12 - Gastroenterologiadiscrimination ability; hepatocellular carcinoma; homogeneity; monotonicity of gradients; prognostic performance; prognostic systembusiness.industryprognostic systemExternal validationMono-tonicity of gradienthepatocellular carcinomamedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSettore MED/18homogeneityOncology030220 oncology & carcinogenesisHepatocellular carcinomaPopulation data030211 gastroenterology & hepatologyGeneral healthdiscrimination abilityLiver dysfunctionbusinessprognostic performancedescription
Simple Summary This review proposes a comprehensive overview of the main prognostic systems for HCC classified as prognostic scores, staging systems, or combined systems. Prognostic systems for HCC are usually compared in terms of homogeneity, monotonicity of gradients, and discrimination ability. However, despite the great number of published studies comparing HCC prognostic systems, it is rather difficult to identify a system that could be universally accepted as the best prognostic scheme for all HCC patients encountered in clinical practice. In order to give a contribute in this topic, we conducted a study aimed at externally validate the MESH score and the CNLC classification using the ITA.LI.CA database. Abstract Prognostic assessment in patients with HCC remains an extremely difficult clinical task due to the complexity of this cancer where tumour characteristics interact with degree of liver dysfunction, patient general health status, and a large span of available treatment options. Several prognostic systems have been proposed in the last three decades, both from the Asian and European/North American countries. Prognostic scores, such as the CLIP score and the recent MESH score, have been generated on a solid statistical basis from real life population data, while staging systems, such as the BCLC scheme and the recent CNLC classification, have been created by experts according to recent HCC prognostic evidences from the literature. A third category includes combined prognostic systems that can be used both as prognostic scores and staging systems. A recent example is the ITA.LI.CA prognostic system including either a prognostic score and a simplified staging system. This review focuses first on an overview of the main prognostic systems for HCC classified according to the above three categories, and, second, on a comprehensive description of the methodology required for a correct comparison between different systems in terms of prognostic performance. In this second section the main studies in the literature comparing different prognostic systems are described in detail. Lastly, a formal comparison between the last prognostic systems proposed for each of the above three categories is performed using a large Italian database including 6882 HCC patients in order to concretely apply the comparison rules previously described.
year | journal | country | edition | language |
---|---|---|---|---|
2021-04-02 | Cancers |